Khalid Fouda, Sherif Soliman, Hamdan Al Hazmi, Mohamed Seida, Amenah Khatab
Department of Surgery, Division of Urology, College of Medicine, King Khalid University Hospital, Riyadh, Saudi Arabia
Introduction: Botulinum toxin, first isolated by Van Emengem in 1897, is the most potent biological toxin known to man. Through basic research, clinicians have been able to transform this lethal toxin into a health benefit. In urology it was initially used to treat spinal cord injured patients who suffers from detrusor external sphincter dyssnergia. More recently Schurch and colleagues reported successful treatment of detrusor hyper-reflexia using intravesical botulinum toxin type-A (Botox®) which was followed by the initial clinical application in children suffering from neuropathic bladder with encouraging result.
Aim of the Study: In this study, we examined the effect of botulinum-A toxin on children with neuropathic bladder, and to see whether botulinum-A toxin can be used alone in the management of refractory neuropathic bladder or better in conjunction with oxybutinin.
Materials and Methods: Between October 2003 and October 2005, 20 children with mean age of 5.7 years (2-10 + SD2.2) had botulinum toxin type A (Botox®) injection for the treatment of neuropathic bladder secondary to myelomeningiocele. All patients were on clean intermittent catheterization and anti-cholenergic medication, but are still showing a non-compliant bladder. The 20 patients were randomized divided into two groups. In group 1 (10 patients) oxybutinin was continued throughout the study and in group 2 (10 patients) oxybutinin was stopped at the day of the (Botox®)) injection and continued off oxybutinin through out the study. A urodynamic study was repeated within a week before the procedure and cystoscopic injection of 12 u/kg of (Botox®)) (maximum 300 u) was done in an infection free bladder. A follow up urodynamic study was done at one month, 3 months, and 6 months follow up.
Results: The maximum bladder capacity increased from 105 ml ± 66 (range 15 to 277) to 156 ml ± 106 (range 50 to 500) (p < 0.012), 143 ± 107 (45-450) (NS) and 135 (21-250) (p < 0.014) at 1, 3, and 6 months respectively. The maximal detrusor pressure decreased significantly from 79 cm H2O ± 39 (36-209) to 56 cm H2O ± 22 (20-100) (p < 0.010), 52 cm H2O ± 18 (22-90) (p < 0.005), and 51 cm H2O ± 16 (18-95) (p < 0.007) at 1, 3, and 6 months respectively. Comparing group 1 and 2 there was no statistical difference in all parameters at any point. From the clinical point of view, out of 14 incontinent patients, 8 (57.1%) patients showed complete continence after treatment, while 3 (21.4%) reported mild to moderate improvement and 3 (21.4%) showed no improvement. None of our patients had side effects related to the procedure or the material used.
Conclusion: Botulinum A toxin injection into the hyper reflexive detrusor muscle seems to cause significant improvement of the bladder function in both urodynamic and clinical parameters. There was no clinical or urodynamic sequel from stopping oxybutinin chloride during the study. Accordingly our results confirm that this new treatment is safe and valuable and can be used as a solo treatment for refractory cases of neuropathic bladder.
Presented at the: 18th Saudi Urological Conference King Abdulaziz University Hospital 20-23 February 2006 (21-24 Muharram 1427)